Literature DB >> 23813105

Intravitreal Ranibizumab for myopic choroidal neovascularization after pars plana vitrectomy and silicone oil tamponade.

Maria Lucia Cascavilla1, Giuseppe Querques, Lea Querques, Marco Codenotti, Francesco Bandello.   

Abstract

PURPOSE: To report on intravitreal Ranibizumab for intervening myopic choroidal neovascularization (CNV) in a case of retinal detachment successfully repaired with pars plana vitrectomy and silicone oil tamponade.
METHODS: Intravitreal ranibizumab was performed in a 67-year-old woman with CNV complicating pathologic myopia. The patient had previously undergone vitrectomy and silicone oil tamponade for retinal detachment.
RESULTS: At 2 months from intravitreal ranibizumab, best-corrected visual acuity (BCVA) improved from count fingers to 20/100, and intraocular pressure (IOP) was 16 mm Hg. Fluorescein angiography (FA) and spectral-domain optical coherence tomography (SD-OCT) showed resolution of late leakage and subretinal/intraretinal fluid, respectively.
CONCLUSIONS: Administration of intravitreal anti-V EGF in patients with silicone oil as intraocular tamponade may represent an intriguing treatment option. Our results suggest that intravitreal injections of Ranibizumab may lead to a rapid improvement in both functional (BCVA) and morphologic (FA and SD-OCT) parameters of CNV activity, without significant rise in IOP, in eyes with silicone oil as intraocular tamponade.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23813105     DOI: 10.5301/ejo.5000337

Source DB:  PubMed          Journal:  Eur J Ophthalmol        ISSN: 1120-6721            Impact factor:   2.597


  2 in total

1.  Anti-VEGF therapy in a silicone oil-filled myopic eye with choroidal neovascularisation.

Authors:  Jay Chhablani; Raja Narayanan
Journal:  BMJ Case Rep       Date:  2015-04-13

2.  Concurrent management of myopic choroidal neovascularization and rhegmatogenous retinal detachment with intravitreal antivascular endothelial growth factor during primary retinal detachment repair.

Authors:  Kumar Saurabh; Rupak Roy; Nicey Roy Thomas; Maitreyi Chowdhury
Journal:  Indian J Ophthalmol       Date:  2018-03       Impact factor: 1.848

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.